Abstract
The aim of the present study was to investigate the prognostic value of the combination of preoperative platelet count (PLT) and mean platelet volume (MPV) in patients with primary operable non-small cell lung cancer (NSCLC). We retrospectively analysed data from 546 patients with NSCLC who underwent complete resection at our institution from 2006 to 2010. Patients’ clinical characteristics and laboratory test data at initial diagnosis were collected. Both preoperative PLT and MPV (COP-MPV) were calculated on the basis of the data obtained using the recommended cut-off values of 300 × 109 L−1 and 11.0 fL, respectively. Patients with both an elevated PLT (≥300× 109 L−1) and a decreased MPV (<11.0 fL) were assigned a score of 2, and patients showing one or neither were allocated a score of 1 or 0, respectively. Multivariate analysis of the 9 clinical laboratory variables selected by univariate analysis revealed that preoperative COP-MPV was a significantly independent prognostic factor for overall survival (OS) (hazard ratio, 1.775; 95% confidence interval, 1.500–2.101; P< 0.001) and disease-free survival (DFS) (hazard ratio, 1.719; 95% confidence interval, 1.454–2.033; P< 0.001). In subgroup analyses for tumour pathological stage (I/II/IIIA) patients, we found that the level of COP-MPV was significantly associated with OS and DFS in each subgroup (P< 0.001, P< 0.001, P<0.001 for OS and P<0.001, P< 0.001, P=0.001 for DFS, respectively). In conclusion, the preoperative COP-MPV is a promising predictor of postoperative survival in patients with NSCLC and could classify these patients into three independent groups before surgery.
Highlights
Non-small cell lung cancer (NSCLC), which accounts for approximately 80% of all lung cancers, is the most common cause of cancer-related deaths worldwide [1]
Multivariate analysis of the 9 clinical laboratory variables selected by univariate analysis revealed that preoperative COP-mean platelet volume (MPV) was a significantly independent prognostic factor for overall survival (OS) and disease-free survival (DFS)
We demonstrated that preoperative COPMPV was significantly related to DFS and OS (HR, 1.719; 95%confidence interval (CI), 1.454–2.033; P
Summary
Non-small cell lung cancer (NSCLC), which accounts for approximately 80% of all lung cancers, is the most common cause of cancer-related deaths worldwide [1]. Several publications have reported prognostic predictors for patients with NSCLC; most of these survival-related factors cannot be obtained preoperatively. Some of these factors are only used as research tools. The relation between thrombocytosis and poor prognosis of multiple solid tumours, such as lung, gastric, ovarian and colon cancers [7,8,9,10], has been reported. A recent study has investigated the prognostic value of combining the PLT with MPV (COP-MPV) to predict post-surgical survival in oesophageal squamous cell cancer (ESCC) patients [19]. Studies regarding the prognostic impact of PLT combined with MPV in patients with resected NSCLC have not been reported. We retrospectively evaluated the prognostic significance of preoperative COP-MPV in primary operable patients with NSCLC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
